language
Language
Englishchevron_right
attach_money
Currency
$USDchevron_right
dark_mode
Dark Mode
policy
Privacy Policy
gavel
Terms of Service
MCKMCK

$845.46

+4.71
arrow_drop_up0.56%
Current Market·update13 Nov 2025 17:44
Day's Range
836.95-849.7416
52-week Range
558.13-867.63

Chart

Loading chart...

Performance

Key Stats

Next Earnings Date2025-11-05
Next Earnings TimeAfter Market Close
Volume180.34K
Average Volume 30d724.55K

AI MCK Summary

Powered by LiveAI
💰
25.5
Valuation (P/E Ratio)
Reasonable valuation given its performance metrics.
📈
0.152
EPS Growth (YoY)
Positive year-over-year earnings growth observed.
Show More 🔒

AI Scoreboard

Powered by LiveAI
🔒

Overall Analysis

Buy
72

McKesson Corporation exhibits strong fundamental performance with consistent revenue growth and profitability. While its valuation is currently on the higher side, its significant market position and consistent dividend payments make it an attractive long-term investment. Technical indicators suggest a neutral to slightly bearish short-term outlook, but the overall trend remains positive.

Strong

Thematic

80

McKesson is well-positioned within the healthcare distribution and services sector, benefiting from demographic trends and the increasing complexity of pharmaceutical supply chains. Its focus on technology solutions for healthcare providers and its role in medical-surgical supply distribution further solidify its thematic relevance.

Strong

Fundamental

85

McKesson demonstrates robust financial health with strong revenue growth, consistent profitability, and a manageable debt level. Its efficient operations and significant market share contribute to its strong fundamental standing. The company also provides a reliable dividend.

Neutral

Technical

61

McKesson's stock is currently trading below key short-term moving averages and exhibits mixed oscillator signals, suggesting a period of consolidation or a minor pullback. The longer-term trend remains positive, but immediate technical indicators suggest caution.

FactorScore
Healthcare Demand & Demographics90
Pharmaceutical Supply Chain Complexity85
Healthcare Technology & Solutions75
Medical-Surgical Supply Chain70
Regulatory Landscape65
FactorScore
Valuation60
Profitability75
Growth70
Balance Sheet Health70
Cash Flow85
Dividend70
FactorScore
Trend Analysis60
Momentum55
Volume Confirmation70
Support & Resistance65
Oscillators50

AI Investing Checklist

Powered by LiveAI
thumb_up

Bullish Points (6)

Earnings Performance chevron_right

Consistent EPS Surprises

McKesson Corporation (MCK) has consistently exceeded earnings per share (EPS) estimates in the majority of its recent quarters, indicating robust operational execution and effective cost management. For example, Q4 2024 reported EPS of $7.07, beating the estimate of $6.88.

Valuation chevron_right

Attractive P/E Ratio Relative to TTM Earnings

The trailing twelve months (TTM) P/E ratio of 27.63 is reasonable given the company's earnings and projected growth, especially when compared to its industry peers. The PE ratio based on TTM earnings of 27.63 offers a potentially favorable entry point for long-term investors.

Show More 🔒
thumb_down

Bearish Points (7)

Valuation Risk chevron_right

High Forward P/E Multiple

The forward P/E ratios (e.g., 66.6 in 2025Q1) appear high compared to the trailing P/E, suggesting that future earnings growth is already significantly priced into the stock, potentially leading to overvaluation if growth targets are not met.

Growth Deceleration (Potential) chevron_right

Mixed Revenue Trends

While annual revenue shows growth, quarterly revenue figures can be volatile. For example, the reported revenue for 2024Q2 was $79.28 billion, while 2024Q3 reached $93.65 billion, indicating significant quarterly fluctuations that warrant close monitoring.

Show More 🔒

Calendar

June 2025

2

Ex-Dividend Date

July 2025

1

Next Dividend Date

August 2025

7

Next Earnings Date

EPS Est.
Revenue Est.

H: $8.49

A: $8.16

L: $7.78

H: 99.18B

A: 96.05B

L: 92.96B

Profile

Employees (FY)43K
ISIN-
FIGI-

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners to address challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver solutions to help people get the medicine needed to live healthier lives; and provides medication access and affordability, prescription decision support, prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services, as well as electronic prior authorization services. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, biomedical maintenance, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, post-acute care facilities, hospital reference labs, and home health care agencies. The International segment delivers deliver medicines, supplies, and information technology solutions to retail pharmacies, hospitals, long-term care centers, clinics and institutions; and provides logistics and distribution services for manufacturers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

Seasonals

2025
2024
2023
2022
2021

Price Target

768.50 USD

The 39 analysts offering 1 year price forecasts for MCK have a max estimate of 824.00 and a min estimate of 610.00.

Debt Level and Coverage

Debt
Free cash flow
Cash & equivalents

Financial Position Analysis

Assets
Liabilities

Ownership

Free Float shares
125M (100.01%)
Closely held shares
-14.3K (-0.01%)
125M
Free Float shares
125M (100.01%)
Closely held shares
-14.3K (-0.01%)

Capital Structure

Market cap
88.71B
Debt
7.39B
Minority interest
0.00
Cash & equivalents
5.69B
Enterprise value
90.4B

Valuation - Summary

Market Cap
88.7B
Net income
2.38B(2.68%)
Revenue
280B(315.39%)
88.7B
Market Cap
88.7B
Net income
2.38B(2.68%)
Revenue
280B(315.39%)
Price to earning ratio (P/E)37.30x
Price to sales ratio (P/S)0.30x

Valuation - Ratios

P/E
P/S

Revenue to Profit Conversion

Revenue
359.05B
COGS
345.73B
Gross Profit
13.32B
OpEx
8.51B
Operating Income
4.82B
Other & Taxes
1.52B
Net Income
3.29B

Balance Sheet

Total assets
Total liabilities
Liabilities to assets %

Income Statement

Revenue
Net Income
Net Margin

Cash Flow

Operating Cash Flow
Investing Cash Flow
Financing Cash Flow
Show More 🔒